Psilocybin For Depression Looks Less Revolutionary When Studies Are Done Right

Psychedelic Therapy Shows No Advantage Over Antidepressants Under Fair Comparison, Study Finds

Psychedelic-assisted therapy has been hailed as a breakthrough for depression, with clinical trial results suggesting it leaves traditional antidepressants in the dust. A major new analysis, however, suggests those eye-popping numbers may have less to do with the psychedelics themselves and more to do with a flaw in how the studies were designed.

When researchers put psychedelic therapy head-to-head against standard antidepressants under fair conditions, the apparent advantage largely disappears. Published in JAMA Psychiatry, the meta-analysis, a large-scale study pooling results from multiple clinical trials, found no meaningful difference between the two treatments in reducing depression symptoms.

For the millions of Americans managing depression, and the many following psychedelic research with hope, that is a significant finding.

Why Psychedelic Therapy for Depression Seemed So Promising

To understand the new analysis, it helps to understand why psychedelic-assisted therapy looked so impressive in the first place.

In clinical trials, patients are typically divided into a treatment group and a placebo group, with neither side knowing who got what. In psychedelic trials, the active treatment involves drugs like psilocybin, the compound in so-called “magic mushrooms,” administered in a supervised setting alongside hours of guided therapy. Those in the placebo group receive an inert pill and wait.

On standard depression rating scales, psychedelic therapy appeared to beat placebo by about 7.3 points on average. Traditional antidepressants beat placebo by only about 2.4 points. That gap made psychedelics look like a generational leap forward.

But there was a fundamental problem. People who take a powerful psychedelic almost always know they took it. The intense, hours-long hallucinatory experience is unmistakable. In psychedelic trials, 90 to 95 percent of patients correctly identified that they had received the real drug. In antidepressant trials, that figure was about 63 percent. Knowing one has received a potentially transformative treatment can itself improve outcomes, an effect well-documented in medical research. Because psychedelic trial participants almost universally knew they had taken the drug, blinding was often compromised in practice.

The Study That Leveled the Playing Field

A team from the University of California Los Angeles, Imperial College London, and UC San Francisco addressed this by changing the comparison entirely. Rather than measuring psychedelic therapy against a blinded placebo, they compared it to open-label antidepressant treatment, where patients also knew they were receiving medication. Under those conditions, both groups would share the same psychological boost of knowing they were being treated.

Drawing from PubMed, the team analyzed 24 clinical trials: 8 psychedelic therapy trials with 249 patients and 16 open-label antidepressant trials involving 7,921 patients. Drugs in the antidepressant trials included familiar names like escitalopram, fluoxetine, sertraline, and venlafaxine.

After running the numbers through multiple statistical models, the results consistently showed that psychedelic-assisted therapy was not more effective than open-label antidepressants. On the depression rating scale, the estimated difference between the two treatments was just 0.3 points, and it actually tilted slightly in favor of the antidepressants, a gap too small to be statistically or clinically meaningful.

Psychedelic Therapy for Depression and the “Know-Cebo” Problem

Beyond the main finding, a separate issue had quietly inflated the reputation of psychedelic therapy: what happens to the placebo group.

In most drug trials, even patients who receive a placebo tend to get somewhat better. The experience of being cared for, monitored, and given something to take has a real, documented effect on mood. In psychedelic trials, that dynamic broke down entirely. Because the preparation for a psychedelic session involves weeks of intensive therapy designed to build anticipation for what researchers describe as a “transformative, spiritual experience,” patients who end up receiving a placebo on dosing day face a particular kind of letdown. They are, according to the paper’s authors, “often bored for the 6 to 8 hours they have to remain on site.” In some psychedelic trials, depression scores in the placebo group actually got worse.

Researchers attribute much of this to what they describe as the “know-cebo effect,” defined in the paper as “the disappointment patients feel when they realize they are in the control group.” When the placebo group sinks, the active treatment looks more powerful by comparison, even if the drug’s actual effect hasn’t changed at all. According to the authors’ calculations, this suppressed placebo response may account for roughly 55 percent of psychedelics’ apparent advantage over placebo in prior trials. A large prior analysis of 304 antidepressant placebo groups, by contrast, found that patients improved in every single one.

What the Findings Do and Don’t Mean

Researchers were careful about what their analysis cannot settle. The authors note limitations including that psychedelic trials have disproportionately enrolled highly educated patients and underrepresented racial minorities, which may skew results in psychedelics’ favor. Antidepressant trials also measured outcomes at around eight weeks, while psychedelic trials checked in at roughly three and a half weeks, a timing gap that likely advantages the faster-acting psychedelics.

Focused entirely on symptom reduction, the study did not weigh side effects, quality of life, or long-term outcomes. One earlier direct comparison of psilocybin and escitalopram found no difference on the primary depression measure, but psilocybin patients reported greater functional improvements at six months, something this analysis was not built to detect.

Still, the authors were direct about what the evidence does show: “PAT’s lack of superiority compared with TADs under equal-unblinding conditions argues against overly optimistic narratives about PAT’s potential and highlights the importance of blinding integrity when evaluating novel treatments.”

Psychedelic therapy may yet prove useful for specific patients or conditions. But the claim that it is categorically more powerful than existing antidepressants, a claim that has driven years of breathless headlines and hundreds of millions in investment, is less certain than those claims suggested.

---

Disclaimer: This article is based on a systematic review and meta-analysis. It is intended for informational purposes only and does not constitute medical advice. Anyone experiencing depression or considering changes to a treatment plan should consult a qualified healthcare professional.

---